153 related articles for article (PubMed ID: 21955311)
1. AFX: what we now know.
McCalmont TH
J Cutan Pathol; 2011 Nov; 38(11):853-6. PubMed ID: 21955311
[No Abstract] [Full Text] [Related]
2. Correction and clarification regarding AFX and pleomorphic dermal sarcoma.
McCalmont TH
J Cutan Pathol; 2012 Jan; 39(1):8. PubMed ID: 22211329
[No Abstract] [Full Text] [Related]
3. Atypical fibroxanthoma.
Weedon D; Van Deurse M
J Cutan Pathol; 2012 May; 39(5):565. PubMed ID: 22443422
[No Abstract] [Full Text] [Related]
4. I double dare me.
McCalmont TH
J Cutan Pathol; 2012 Jan; 39(1):5-7. PubMed ID: 22211328
[No Abstract] [Full Text] [Related]
5. Red is dead.
McCalmont TH
J Cutan Pathol; 2012 Mar; 39(3):315-6. PubMed ID: 22335589
[No Abstract] [Full Text] [Related]
6. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma.
Wieland CN; Dyck R; Weenig RH; Comfere NI
J Cutan Pathol; 2011 Nov; 38(11):884-8. PubMed ID: 21883368
[TBL] [Abstract][Full Text] [Related]
7. [Fibrohistiocytic tumor of skin].
Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):134-7. PubMed ID: 23710926
[No Abstract] [Full Text] [Related]
8. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
9. Atypical fibroxanthoma.
Ziemer M
J Dtsch Dermatol Ges; 2012 Aug; 10(8):537-50. PubMed ID: 22709412
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma.
Bull C; Mirzabeigi M; Laskin W; Dubina M; Traczyc T; Guitart J; Gerami P
J Cutan Pathol; 2011 Aug; 38(8):631-5. PubMed ID: 21623867
[TBL] [Abstract][Full Text] [Related]
11. AFX ex BFX.
McCalmont TH; Scheinberg RS
J Cutan Pathol; 2011 May; 38(5):387-90. PubMed ID: 21443559
[No Abstract] [Full Text] [Related]
12. Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy.
Koch M; Freundl AJ; Agaimy A; Kiesewetter F; Künzel J; Cicha I; Alexiou C
Anticancer Res; 2015 Nov; 35(11):5717-35. PubMed ID: 26503993
[TBL] [Abstract][Full Text] [Related]
13. Pleomorphic spindle cell dermal neoplasm with dot-like keratin reactivity: keratin-positive AFX or carcinoma?
Ellis R; Chase E; Barland A; Rajpara A; Fraga GR
J Cutan Pathol; 2015 Nov; 42(11):847-52. PubMed ID: 26041010
[TBL] [Abstract][Full Text] [Related]
14. h-caldesmon immunoreactivity in atypical fibroxanthoma: implications for the differential diagnosis.
Martinez-Ciarpaglini C; Agustí J; Alvarez E; Hueso L; Terrádez L; Monteagudo C
Pathology; 2018 Apr; 50(3):358-361. PubMed ID: 29490873
[No Abstract] [Full Text] [Related]
15. Cutaneous soft tissue tumors that make you say, "oh $*&%!".
Patel RM; Billings SD
Adv Anat Pathol; 2012 Sep; 19(5):320-30. PubMed ID: 22885381
[TBL] [Abstract][Full Text] [Related]
16. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
Clarke LE; Frauenhoffer E; Fox E; Neves R; Bruggeman RD; Helm KF
J Cutan Pathol; 2010 Jul; 37(7):737-43. PubMed ID: 20175824
[TBL] [Abstract][Full Text] [Related]
17. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
18. Best practices in diagnostic immunohistochemistry: pleomorphic cutaneous spindle cell tumors.
Folpe AL; Cooper K
Arch Pathol Lab Med; 2007 Oct; 131(10):1517-24. PubMed ID: 17922587
[TBL] [Abstract][Full Text] [Related]
19. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin.
Rizzardi C; Angiero F; Melato M
Anticancer Res; 2003; 23(2C):1847-51. PubMed ID: 12820468
[TBL] [Abstract][Full Text] [Related]
20. Low proliferative activity in common dermatofibroma does not necessarily guarantee a low proliferation in all dermatofibroma variants.
Fernandez-Flores A
Arch Pathol Lab Med; 2008 Feb; 132(2):160; author reply 160-1. PubMed ID: 18251566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
